Jon C Cook
Overview
Explore the profile of Jon C Cook including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hollingshead B, Tomlinson L, Finley J, Doshna C, Ritenour C, Barricklow J, et al.
Regul Toxicol Pharmacol
. 2021 Apr;
123:104934.
PMID: 33872740
Systemic toxicity assessments for oral or parenteral drugs often utilize the concentration of drug in plasma to enable safety margin calculations for human risk assessment. For topical drugs, there is...
2.
Cook J, Burns Naas L, Ganey P
Toxicol Sci
. 2020 May;
175(1):1-2.
PMID: 32365210
No abstract available.
3.
Kakiuchi-Kiyota S, Obert L, Crowell D, Xia S, Roy M, Coskran T, et al.
Toxicol Pathol
. 2020 Jan;
48(3):481-493.
PMID: 31918642
Several chemicals and pharmaceuticals increase the incidence of hemangiosarcomas (HSAs) in mice, but the relevance to humans is uncertain. Recently, canine HSAs were identified as a powerful tool for investigating...
4.
Peng Q, Mechanic J, Shoieb A, Pardo I, Schaevitz L, Fenyk-Melody J, et al.
PLoS One
. 2019 Jan;
14(1):e0210995.
PMID: 30677061
Chemotherapy-induced peripheral neuropathy (CiPN) is a serious adverse effect in the clinic, but nonclinical assessment methods in animal studies are limited to labor intensive behavioral tests or semi-quantitative microscopic evaluation....
5.
Cook J, Wu H, Aleo M, Adkins K
J Toxicol Sci
. 2018 Oct;
43(10):565-577.
PMID: 30298845
Precision medicine is an approach to developing drugs that focuses on employing biomarkers to stratify patients in clinical trials with the goal of improving efficacy and/or safety outcomes, ultimately increasing...
6.
Cook J, Obert L, Koza-Taylor P, Coskran T, Opsahl A, Ziemek D, et al.
Toxicol Sci
. 2017 Oct;
161(1):58-75.
PMID: 28973697
Pharmaceuticals and chemicals produce hemangiosarcomas (HS) in mice, often by nongenotoxic, proliferative mechanisms. A mode-of-action (MOA) for hemangiosarcoma was proposed based on information presented at an international workshop (Cohen et...
7.
Liu C, Berryman E, Zakur D, Shoieb A, Pardo I, Boucher M, et al.
J Appl Toxicol
. 2017 Aug;
38(2):193-200.
PMID: 28815646
Chemotherapy-induced peripheral neuropathy (CiPN) is a frequent adverse effect in patients and a leading safety consideration in oncology drug development. Although behavioral assessment and microscopic examination of the nerves and...
8.
Wegner C, Goodwin A, Cook J, Allamneni K, Sohn J, McVean M
Int J Toxicol
. 2017 Jun;
36(4):340-349.
PMID: 28578602
There are many reasons that molecules fail to progress to market and various principles of risk-benefit decisions that can help drive the molecule through development. This symposium included discussions on...
9.
Kakiuchi-Kiyota S, Crabbs T, Arnold L, Pennington K, Cook J, Malarkey D, et al.
Toxicol Pathol
. 2012 Nov;
41(5):709-21.
PMID: 23125116
It is unclear whether the process of spontaneous and chemically induced hemangiosarcoma and hemangioma formation in mice involves the transformation of differentiated endothelial cells (ECs) or recruitment of multipotential bone...
10.
Criswell K, Cook J, Wojcinski Z, Pegg D, Herman J, Wesche D, et al.
Toxicol Sci
. 2012 Apr;
128(1):57-71.
PMID: 22539620
Pregabalin increased the incidence of hemangiosarcomas in carcinogenicity studies of 2-year mice but was not tumorigenic in rats. Serum bicarbonate increased within 24 h of pregabalin administration in mice and...